Publications

View and download slide summaries of the latest original articles focusing on therapies in immune-mediated inflammatory diseases including rheumatology, dermatology, and gastroenterology. All materials produced by the team are subsequently reviewed and approved by individual Steering Committee members.

July 2023

Tofacitinib frente a metotrexato como Fármacos Antirreumáticos Modificadores de la Enfermedad de Primera Línea en el Tratamiento de la Artritis Reumatoide: Un ensayo controlado aleatorizado abierto

Int J Rheum Dis. 2023;26(9):1729–1736 doi: 10.1111/1756-185X.14801

Khan MM,

Ahmed S,

This single-centre study by Khan, et al. suggests that high-dose methotrexate (25 mg/week, subcutaneously) may be as efficacious as tofacitinib in patients with established RA who are DMARD naïve or have not received a therapeutic dose of DMARDs.

Keywords:

June 2023

Efecto del índice de masa corporal en la respuesta al tratamiento con DMARD biológicos/sintéticos dirigidos en pacientes con artritis reumatoide, artritis psoriásica o espondiloartritis axial. Una revisión sistemática

Autoimmunity Reviews 22 (2023) 103357

Chrysoula G. Gialouri,

Maria Pappa,

Gerasimos Evangelatos,

Elena Nikiphorou,

George E. Fragoulis

The study demonstrated that obesity is a factor that could play a role in treatment decision-making in people living with inflammatory arthritis (IA). It appears that efficacy of TNFi is affected by patients’ weight/BMI in all forms of IA, while this is not the case for TCZ and ABA in RA, as well for IL-17 and IL-23 inhibitors in PsA.

Keywords:

Inhibición de la Interleuquina-17 en Pacientes con Artritis Psoriásica Oligoarticular

Rheumatol Ther. 2023;10(4):849-860 doi: 10.1007/s40744-023-00548-y

Ogdie A,

Secukinumab reduced disease activity across a range of outcome measures by week 12, with sustained responses through 52 weeks.

Keywords:

May 2023

A Patient with Adalimumab-induced Refractory Paradoxical Palmoplantar Pustulosis was Successfully Treated by Ixekizumab: A Case Report

Clin Cosmet Investig Dermatol. 2023;16:879–881 doi 10.2147/CCID.S406164

Shao XY,

Xiong JX,

Chen AJ,

Huang K,

Wang P

Ixekizumab, has been shown to be efficacious against paradoxical palmoplantar pustulosis which has been reported following the administration of therapeutic TNFi. Following the increased use of biologic therapies that improve patients’ quality of life are causing paradoxical adverse effects

Keywords:

When to Start Secukinumab Treatment in Patients with Axial Spondyloarthropathy: Before or After Anti-TNFα Treatment?

Reumatol Clin. 19 (2023); 175–179 doi 10.1016/j.reumae.2022.03.007

Ak T,

Mustafayeva L,

Celik Y,

Ayla A,

Urgurlu S

Secukinumab, an IL-17A monoclonal antibody, was shown to have remarkable efficacy for axSpA in the MEASURE 2 and MEASURE 3 trials. Previous studies have concluded that secukinumab was more efficacious in TNFi-naïve patients.

Keywords:

Immunogenicity and Safety of Adjuvanted Recombinant Zoster Vaccine in Rheumatoid Arthritis Patients on Anti-Cellular Biologic Agents or JAK Inhibitors: A Prospective Observational Study

Int JMol Sci 2023;24(8):6967 doi 10.3390/ijms24086967

A prospective observational study showed that recombinant zoster vaccine (RZV) immunogenicity is not impaired in RA patients on JAK inhibitors or anti-cellular bDMARDs.

Keywords:

Evaluation of BMS-986142, a Reversible Bruton’s Tyrosine Kinase Inhibitor, for the Treatment of Rheumatoid Arthritis: A Phase 2, Randomised, Double-blind, Dose-ranging, Placebo-controlled, Adaptive Design Study

Lancet Rheumatol 2023;5:e263–73 doi 10.1016/S2665-9913(23)00089-9

Conaghan PG,

Nowak M,

Du S,

Luo Y,

Fura A,

Investigators from a phase 2 study concluded that further investigation with BMS-986142 (a novel BTK) in people with RA is not necessary.

Keywords:

BTK,
Phase 2

Enthesitis in Patients with Psoriatic Arthritis Treated with Secukinumab or Adalimumab: a post hoc Analysis of the EXCEED Study

Rheumatology (Oxford).2023;kead181. doi 10.1093/rheumatology/kead181.

Results from the 52-week phase 3 EXCEED study showed that secukinumab and adalimumab both display similar efficacy in time to resolution of enthesitis, in patients with PsA, irrespective of baseline enthesitis severity and individual site distribution.

Keywords:

Efficacy and Safety of Upadacitinib in Patients with Active Psoriatic Arthritis and Axial Involvement: Results From Two Phase 3 Studies

Arthritis Res Ther. 2023;25(1):56 doi 10.1186/s13075-023-03027-5

Ranza R,

Gao T,

Kato k,

Song IH,

Granz F,

Deodhar A

Evidence from two phase 3 RCTs showed that patients with PsA and axial involvement had greater responses when treated with a once-daily oral dose of 15 mg upadacitinib versus placebo, and a similar or greater response versus adalimumab. Safety results were comparable between patients with or without axial involvement.

Keywords:

April 2023

Diferencias de sexo en la eficacia, seguridad y persistencia de los pacientes con artritis psoriásica tratados con tofacitinib: Un análisis post hoc de ensayos de fase 3 y extensión a largo plazo

RMD Open 2023;9:e002718 doi 10.1136/rmdopen-2022-002718

Eder L,

Mease P,

Luna R,

Ogdie A,

Kinch C,

Evidence from two phase 3 RCTs and one LTE shows that while tofacitinib efficacy exceeds placebo in both sexes and is comparable between sexes, males are more likely to achieve minimal disease activity than females.